Singapore markets closed

Straits Times Index
3,176.51
-11.15(-0.35%)
Nikkei
37,068.35
-1,011.35(-2.66%)
Hang Seng
16,224.14
-161.73(-0.99%)
FTSE 100
7,895.85
+18.80(+0.24%)
Bitcoin USD
63,842.97
-461.77(-0.72%)
CMC Crypto 200
1,371.97
+59.35(+4.52%)

Merrimack Pharmaceuticals, Inc. (MACK)

NasdaqGM - NasdaqGM Real-time price. Currency in USD

Add to watchlist

14.72

+0.04

(+0.27%)

At close: 04:00PM EDT

14.68

-0.04

(-0.27%)

After hours:

07:03PM EDT

Trade prices are not sourced from all markets

All

Business Wire
Merrimack Receives $225 Million Milestone Payment from Ipsen
CAMBRIDGE, Mass., March 27, 2024--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and Drug Administration, or FDA, to market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas.
Business Wire
Merrimack Reports Full Year 2023 Financial Results
CAMBRIDGE, Mass., March 07, 2024--Merrimack Reports Full Year 2023 Financial Results
Simply Wall St.
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is definitely on the radar of hedge funds investors who own 35% of the company
Key Insights Significantly high institutional ownership implies Merrimack Pharmaceuticals' stock price is sensitive to...